Experimental combo aims to boost stem cell transplant success for rare blood cancers
NCT ID NCT02512497
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 37 times
Summary
This early-phase study tested whether adding the drug romidepsin to standard chemotherapy before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Researchers enrolled 23 adults to find the safest dose and see if the combination helped patients engraft and survive at least 30 days. The goal was to improve transplant outcomes, not to cure the disease, and patients would still need long-term monitoring and possibly ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.